Migraine Medications Recalled Due to Potential Contamination
Pfizer has recalled two lots of its 40-mg tablet migraine medication Relpax (eletriptan hydrobomide) because they may be contaminated with two different types of dangerous bacteria. The bacteria are Pseudomonas and Burkholderia. When they’re consumed, they can migrate from the intestinal tract to the bloodstream, putting those exposed to the bacteria at risk of serious and even life-threatening infections.
In a press release concerning the recall, Pfizer noted that the risk of serious side effects is low for the general population, but patients with compromised immune systems, cystic fibrosis, and chronic granulomatous disease are at higher risk of suffering serious adverse events if they take contaminated tablets.
Pfizer hasn’t received any customer complaints or reports of adverse health effects related to the potential contamination yet. However, the affected lots were distributed nationwide and to Puerto Rico between June 2019 and July 2019. Affected lots include:
- Lot AR5407, expiration date Feb. 2022, 40 mg strength, 6 tablets
- Lot CD4565, expiration date Feb. 2022, 40 mg strength, 12 tablets
Anyone who purchased or received the affected lots should contact Pfizer to return it. You may be notified by your doctor, pharmacist, or hospital of the recall if you were prescribed the affected medication. Don’t stop taking any medications without speaking to your doctor first.